What factors can cause a rise in lipoprotein(a) (Lp(a)) level from 170 mg/dL to 191 mg/dL over a few years?

What Causes Lipoprotein(a) to Rise Over Time

A modest rise in Lp(a) from 170 to 191 mg/dL over a couple of years is most likely due to normal biological variation rather than a true pathological increase, as Lp(a) levels are predominantly genetically determined (up to 90%) and remain relatively stable throughout adult life. 1

Understanding Lp(a) Biological Variation

The change you're observing (170 to 191 mg/dL, approximately 12% increase) falls well within expected biological variation:

• The biological coefficient of variation (C.V.b) for Lp(a) averages 18% (range 1.7-58%), meaning serial measurements naturally fluctuate even without true changes in underlying Lp(a) levels 2
• For patients with baseline Lp(a) around 59 mg/dL, 95% of follow-up values fell in the range of 34-104 mg/dL over 1.7 years, demonstrating substantial measurement variability 2
• Three to four separate measurements are needed to establish a "true" Lp(a) value due to this inherent variability 2

Potential Causes of Actual Lp(a) Increases

If this represents a true increase rather than biological variation, consider these specific factors:

Kidney Disease (Most Important Modifiable Factor)

• Both nephrotic syndrome and chronic kidney disease increase Lp(a) levels two- to three-fold through different mechanisms 1
• In nephrotic syndrome, Lp(a) biosynthesis increases 1
• In end-stage renal disease, reduced Lp(a) catabolism occurs 1
• Urinary apo(a) significantly decreases once GFR falls below 70 mL/min, contributing to Lp(a) accumulation 1
• In diabetes, Lp(a) elevation relates primarily to the degree of kidney dysfunction rather than diabetes itself 1

Thyroid Dysfunction

• Hypothyroid patients have significantly higher Lp(a) concentrations (10-25% elevation) 1
• Appropriate thyroid hormone replacement leads to Lp(a) reduction toward euthyroid levels 1
• Check TSH if not recently measured

Acute Phase Response

• Lp(a) can act as a positive acute phase reactant with up to two-fold increases, with maximal values occurring 6-8 days after acute events 1
• IL-6 enhancement of apo(a) expression drives this increase 1
• However, evidence is controversial, as some studies show sharp falls during sepsis or burns 1

Medication Effects

• Statins may paradoxically raise Lp(a) levels despite their cardiovascular benefits 1
• Low-saturated fat diets can also increase Lp(a) 1
• Discontinuation of estrogen therapy (if previously on hormone replacement) would increase Lp(a) by up to 37% 1
• Stopping thyroid hormone replacement would increase Lp(a) 1

Pregnancy (If Applicable)

• Lp(a) increases 2.5- to 3-fold during pregnancy, with maximal elevations at weeks 19-20 1

Clinical Approach

Evaluate the following systematically:

1. Renal function: Check serum creatinine, eGFR, and urinalysis for proteinuria 1
2. Thyroid function: Measure TSH and free T4 1
3. Recent acute illness: Review for infections, inflammatory conditions, or cardiovascular events in the past 2-3 weeks 1
4. Medication review: Document any changes in statins, hormone therapy, or thyroid replacement 1
5. Repeat measurement: Obtain 2-3 additional Lp(a) measurements to confirm the trend and account for biological variation 2

Important Caveats

• Lp(a) levels are largely genetically determined and typically remain stable throughout adult life in the absence of secondary causes 1
• The modest 12% increase observed may not represent a clinically significant change given the 18% average biological variation 2
• Assay methodology matters: Ensure measurements used the same assay method, as different assays can yield substantially different results due to apo(a) size polymorphism 1
• Mass-based assays (mg/dL) are less accurate than molar assays (nmol/L) and should ideally be phased out 1